Teleflex (TFX) Tops Q4 EPS by 9c

Teleflex Reports Fourth Quarter and Full Year 2015 Results; Provides 2016 Guidance

Fourth Quarter Revenues of $484.5 million, Up 1.8% Versus Prior Year Period; Up 7.4% on Constant Currency Basis

Fourth Quarter GAAP Diluted EPS of $1.88, Up 70.9% Over the Prior Year Period

Fourth Quarter Adjusted Diluted EPS of $2.01, up 40.6%, net of the Unfavorable Impact From Foreign Currency of Approximately 15.4%

Full Year 2015 Revenues of $1,809.7 million, Down 1.6% Versus Prior Year; Up 5.4% on Constant Currency Basis

Full year 2015 GAAP Diluted EPS of $4.91, Up 19.8% Over the Prior Year

Full Year 2015 Adjusted Diluted EPS of $6.33, up 10.3%, net of the... More

Teleflex Launches New Arrow® VPS® Stylet

WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, announced it has received FDA 510(k) clearance to market a newly designed Arrow® VPS® Stylet. The new design allows Teleflex to provide hospitals with a complete offering of single, double and triple lumen pre-loaded, pressure injectable Arrow® PICC with Chlorag+ard® Technology for use with its current Arrow® VPS® Device platform. Together these technologies provide an easy solution for clinicians who are dedicated to reducing central venous catheter malposition while helping prevent microbial colonization... More